# Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

> **NCT00002517** · PHASE3 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC**

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** cytarabine
- **DRUG:** daunorubicin hydrochloride
- **DRUG:** dexamethasone
- **DRUG:** etoposide
- **DRUG:** idarubicin
- **DRUG:** mitoxantrone hydrochloride
- **DRUG:** thioguanine
- **PROCEDURE:** allogeneic bone marrow transplantation
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00002517
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-03
- **Primary completion:** 2010-05
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2010-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002517

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002517, "Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00002517. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*